Immunome (IMNM) Competitors

Immunome (NASDAQ:IMNM) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Do insiders & institutionals believe in IMNM or SWTX?

44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media favor IMNM or SWTX?

In the previous week, SpringWorks Therapeutics had 46 more articles in the media than Immunome. MarketBeat recorded 50 mentions for SpringWorks Therapeutics and 4 mentions for Immunome. Immunome's average media sentiment score of 1.62 beat SpringWorks Therapeutics' score of 0.38 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SpringWorks Therapeutics	14 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Which has more risk & volatility, IMNM or SWTX?

Immunome has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Do analysts recommend IMNM or SWTX?

Immunome presently has a consensus target price of $25.33, indicating a potential upside of 188.21%. SpringWorks Therapeutics has a consensus target price of $52.57, indicating a potential upside of 13.55%. Given Immunome's stronger consensus rating and higher possible upside, research analysts plainly believe Immunome is more favorable than SpringWorks Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
SpringWorks Therapeutics	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Is IMNM or SWTX more profitable?

SpringWorks Therapeutics has a net margin of -134.73% compared to Immunome's net margin of -3,014.59%. SpringWorks Therapeutics' return on equity of -46.74% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	-3,014.59%	-48.63%	-41.62%
SpringWorks Therapeutics	-134.73%	-46.74%	-41.12%

Does the MarketBeat Community prefer IMNM or SWTX?

SpringWorks Therapeutics received 68 more outperform votes than Immunome when rated by MarketBeat users. However, 77.55% of users gave Immunome an outperform vote while only 68.39% of users gave SpringWorks Therapeutics an outperform vote.

Company	Underperform	Outperform
Immunome	Outperform Votes 38 77.55%	Underperform Votes 11 22.45%
SpringWorks Therapeutics	Outperform Votes 106 68.39%	Underperform Votes 49 31.61%

Which has better earnings & valuation, IMNM or SWTX?

Immunome has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$9.04M	84.60	-$106.81M	-$5.17	-1.70
SpringWorks Therapeutics	$191.59M	18.12	-$325.10M	-$3.48	-13.30

Summary

Immunome beats SpringWorks Therapeutics on 11 of the 18 factors compared between the two stocks.